Summary

From 2025 to 2035, the Circulating Tumor Cells Market is expected to register a CAGR of 8.8%. Adoption accelerates as stakeholders seek higher performance, lower lifecycle costs, and compliance with tightening standards. Significant contributors include emerging markets undertaking capacity expansion, and mature markets prioritizing retrofits and upgrades that deliver measurable savings and reliability.

“Immunomagnetic enrichment is projected to grow at a significant rate from 2025 to 2035.”

Immunomagnetic enrichment continues to gain traction owing to superior performance metrics, better durability, and favorable total cost of ownership. Continuous improvements in materials, design, and integration are lifting efficiency while simplifying installation and upkeep. Vendors are bundling advanced controls and monitoring to enable predictive maintenance and data‑driven optimization, further strengthening this segment’s appeal.

“Cancer research centers is likely to remain the largest end‑user segment.”

Cancer research centers accounts for a sizable share of demand as buyers prioritize dependable quality, safety, and energy savings. Budget reallocation toward long‑life solutions, coupled with incentives and rebates in select markets, is reinforcing adoption. The segment also benefits from a steady pipeline of replacement demand and standardization trends.

“North America is projected to be the fastest‑growing region between 2025 and 2035.”

North America outpaces other regions on the back of policy support, rapid industrial or infrastructure growth, and escalating investment from both public and private stakeholders. Localization of manufacturing, supply‑chain upgrades, and targeted R&D programs contribute to competitive cost structures and quicker time‑to‑market.

Primary Interviews substantiate the findings and outlook: By Company Type – Tier 1 45%, Tier 2 35%, Tier 3 20%; By Designation – C‑level 30%, Directors 29%, Others 41%; By Region – North America 35%, North America 25%, Europe 20%, Middle East & Africa 12%, South America 8%.

Key Players: Leading companies active in the Circulating Tumor Cells Market include Menarini Silicon Biosystems, Bio‑Techne, QIAGEN, Thermo Fisher, Miltenyi Biotec. Strategies span product innovation, regional expansion, and partnerships with channel and technology allies.

Research Coverage: The study defines, segments, and forecasts the Circulating Tumor Cells Market by product/technology, application, end user, and region. It quantifies market size and growth, and provides qualitative insight into regulatory context, supply‑chain dynamics, pricing trends, and competitive positioning. The report also benchmarks offerings and profiles key participants to inform strategy and partnering decisions.

Key Benefits of Buying the Report: (1) Identify growth pockets and align roadmaps with 2025–2035 demand signals; (2) Understand drivers such as efficiency mandates and digitization, as well as restraints including upfront cost or skills gaps; (3) Size opportunities in emerging applications and regions; (4) Anticipate challenges related to standards, procurement cycles, and interoperability, reducing execution risk.

Market Developments: The period is characterized by iterative product refreshes, lighter and more efficient architectures, and software‑enabled services that elevate uptime and user experience. Players are piloting circular‑economy initiatives, broadening aftermarket service portfolios, and co‑developing solutions with customers to accelerate scale.

Fatpos Marketing: Why You Should Purchase It – Access decision‑grade analytics built on triangulated primary and secondary research; track competitors with comparative scorecards; uncover region‑wise opportunity maps and adoption barriers; and translate insights into sales narratives, pricing logic, and partnership plays that improve win rates and ROI.

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Regional Market Share
1.2. Business Trends
1.3. Circulating Tumor Cells Market: COVID-19 Outbreak
1.4. Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2. Research Approach
2.3. Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2. Public Sources
2.6. Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2. Circulating Tumor Cells Market: COVID-19 Impact
3.3. Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Circulating Tumor Cells Market – Industry Insights
4.1. Industry Segmentation
4.2. COVID-19 overview on world economy
4.3. Industry ecosystem Channel analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7. Market Dynamics
7.1. Introduction
7.2. Growth Drivers
7.3. Market Opportunities
7.4. Market Restraints
7.5. Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porters Five Forces
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. Circulating Tumor Cells Market
10.1. Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11. Circulating Tumor Cells Market Size & Forecast 2024A-2034F
11.1. Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1. By Technology
11.3.1.1. CTC Detection and Enrichment Methods
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2. Market Share (%) 2024-2034F
11.3.1.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.2. CTC Direct Detection Methods
11.3.1.2.1. By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3. CTC Analysis
11.3.1.3.1. By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Specimen
11.3.2.1. Blood
11.3.2.1.1. By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Bone Marrow
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2. Market Share (%) 2024-2034F
11.3.2.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Other Body Fluids
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2. Market Share (%) 2024-2034F
11.3.2.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.3. By Product
11.3.3.1. Kits and Reagents
11.3.3.1.1. By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Blood Collection Tubes
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2. Market Share (%) 2024-2034F
11.3.3.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Devices or Systems
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2. Market Share (%) 2024-2034F
11.3.3.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.4. By Application
11.3.4.1. Clinical/Liquid Biopsy
11.3.4.1.1. By Value (USD Million) 2024-2034F
11.3.4.1.2. Market Share (%) 2024-2034F
11.3.4.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.4.2. Research
11.3.4.2.1. By Value (USD Million) 2024-2034F
11.3.4.2.2. Market Share (%) 2024-2034F
11.3.4.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.5. By End User
11.3.5.1. Hospitals
11.3.5.1.1. By Value (USD Million) 2024-2034F
11.3.5.1.2. Market Share (%) 2024-2034F
11.3.5.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.5.2. Clinics
11.3.5.2.1. By Value (USD Million) 2024-2034F
11.3.5.2.2. Market Share (%) 2024-2034F
11.3.5.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.5.3. Research and Academic Institutes
11.3.5.3.1. By Value (USD Million) 2024-2034F
11.3.5.3.2. Market Share (%) 2024-2034F
11.3.5.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.5.4. Diagnostic Centers
11.3.5.4.1. By Value (USD Million) 2024-2034F
11.3.5.4.2. Market Share (%) 2024-2034F
11.3.5.4.3. Y-o-Y Growth (%) 2024-2034F
11.3.5.5. Others
11.3.5.5.1. By Value (USD Million) 2024-2034F
11.3.5.5.2. Market Share (%) 2024-2034F
11.3.5.5.3. Y-o-Y Growth (%) 2024-2034F
12. North America Circulating Tumor Cells Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Technology
12.3.2. By Specimen
12.3.3. By Product
12.3.4. By Application
12.3.5. By End User
12.4. Country
12.4.1. United States
12.4.2. Canada
13. Europe Circulating Tumor Cells Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Technology
13.3.2. By Specimen
13.3.3. By Product
13.3.4. By Application
13.3.5. By End User
13.4. Country
13.4.1. Germany
13.4.2. United Kingdom
13.4.3. France
13.4.4. Italy
13.4.5. Spain
13.4.6. Russia
13.4.7. Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Circulating Tumor Cells Market Size & Forecast 2024A-2034F
14.1. Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Technology
14.3.2. By Specimen
14.3.3. By Product
14.3.4. By Application
14.3.5. By End User
14.4. Country
14.4.1. India
14.4.2. China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Circulating Tumor Cells Market Size & Forecast 2024A-2034F
15.1. Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Technology
15.3.2. By Specimen
15.3.3. By Product
15.3.4. By Application
15.3.5. By End User
15.4. Country
15.4.1. Israel
15.4.2. GCC
15.4.3. North Africa
15.4.4. South Africa
15.4.5. Rest of Middle East and Africa
16. Latin America Circulating Tumor Cells Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Technology
16.3.2. By Specimen
16.3.3. By Product
16.3.4. By Application
16.3.5. By End User
16.4. Country
16.4.1. Mexico
16.4.2. Brazil
16.4.3. Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2024
17.2. Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Illumina, Inc.
18.1.1. Company Overview
18.1.2. Financial Overview
18.1.3. Key Product; Analysis
18.1.4. Company Assessment
18.1.4.1. Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2. QIAGEN N.V.
18.3. Bio-Techne Corporation
18.4. Menarini Silicon Biosystems
18.5. F. Hoffmann-La Roche Ltd.
18.6. ApoCell, Inc.
18.7. Epic Sciences
18.8. Biocept, Inc.
18.9. Ikonisys Inc.
18.10. Cynvenio Biosystems, Inc.
18.11. Fluxion Biosciences, Inc.
18.12. AVIVA Biosciences
18.13. Advanced Cell Diagnostics, Inc.
18.14. Greiner Bio-One International GmbH
18.15. Sysmex Corporation
18.16. Other Prominent Players
19. Appendix
20. Consultant Recommendation